In a report released today, Steven Lichtman from Oppenheimer maintained a Hold rating on Boston Scientific Corp (NYSE: BSX). The company’s shares closed yesterday at $38.40, close to its 52-week high of $38.49.
According to TipRanks.com, Lichtman ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.5% and a 53.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Motus Gi Holdings Inc, and Integra Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $39.56 average price target.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.49 billion and net profit of $555 million. In comparison, last year the company earned revenue of $2.26 billion and had a net profit of $146 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
